{"id":389786,"date":"2022-08-31T00:00:00","date_gmt":"2022-08-31T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfim0004-2022-biopharma-sjogrens-syndrome-niche-rare-disease-landscape-forecast-us-eu5-2022\/"},"modified":"2026-04-14T10:20:50","modified_gmt":"2026-04-14T10:20:50","slug":"nrlfim0004-2022-biopharma-sjogrens-syndrome-niche-rare-disease-landscape-forecast-us-eu5-2022","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfim0004-2022-biopharma-sjogrens-syndrome-niche-rare-disease-landscape-forecast-us-eu5-2022\/","title":{"rendered":"Sj\u00f6gren&#8217;s Syndrome | Niche &#038; Rare Disease Landscape &#038; Forecast | US\/EU5 | 2022"},"content":{"rendered":"<p>Sj\u00f6gren\u2019s syndrome (SS) is a progressive autoimmune disease characterized by chronic inflammation and lymphocytic infiltration of the exocrine glands; the disease may occur alone (primary SS) or with a comorbid autoimmune condition (secondary SS). Symptomatic therapies to treat dry eyes, dry mouth, and\/or specific extraglandular manifestations are the cornerstone of disease management. Systemic manifestations are most often treated with hydroxychloroquine or, in severe cases, systemic immunomodulators (e.g., azathioprine, methotrexate). Therapies with disease-modifying potential are in development for SS (e.g., Novartis\u2019s iscalimab and ianalumab), targeting key pathways believed to drive pathological processes in the disease. These putative disease-modifying therapies have the potential to transform the management of SS, although SS is an indication in which such success has historically been a challenge.<\/p>\n<p><strong>Questions answered <\/strong><\/p>\n<ul>\n<li>How large is the SS population and how will its size change over time?<\/li>\n<li>How is SS currently managed? What are the current treatments, and what drives their use?<\/li>\n<li>Which unfulfilled clinical needs are the most pressing?<\/li>\n<li>Which pipeline products are the most promising, and what sales might they garner in the SS market? What therapies of note are progressing in earlier phases?<\/li>\n<li>What clinical roles will Novartis\u2019s iscalimab and ianalumab play in the evolving SS treatment landscape?<\/li>\n<li>What are the drivers of and constraints in the SS market, and how will the market evolve through 2031?<\/li>\n<\/ul>\n<p><strong>Content highlights <\/strong><\/p>\n<ul>\n<li>Geographies: United States and EU5.<\/li>\n<li>Primary research: Six country-specific interviews with thought-leading SS specialists supported by survey data collected for this study.<\/li>\n<li>Epidemiology: Diagnosed and drug-treated prevalent cases of SS by country, diagnosed prevalence by subtype.<\/li>\n<li>Forecast: Drug-level sales and patient share of key SS therapies through 2031.<\/li>\n<li>Emerging therapies: Phase III\/PR: 1 drug;\u00a0Phase II: 7+ drugs; coverage of select early-phase products.<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Niche &#038; Rare Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p>\u200b\u200b\u200b\u200b\u200b\u200b<\/p>\n<p><strong>Solution enhancement<\/strong><\/p>\n<p>Niche &#038; Rare Disease Landscape &#038; Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389786","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-sjogrens-syndrome","biopharma-geography-us","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389786","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389786\/revisions"}],"predecessor-version":[{"id":576213,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389786\/revisions\/576213"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389786"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}